InStyler Debuts Power Affiliate Program to Boost Creators with Product Launches
'We're about to launch a product that could disrupt the industry in a way that beats everything before it'— Dan Fugardi
LOS ANGELES, CA, UNITED STATES, July 11, 2025 / EINPresswire.com / -- InStyler, the innovative beauty-tech brand behind some of the most iconic hair tools on the market, is now raising the bar for influencer partnerships. The company today announced what it is calling its first version of InStyler's Power Affiliate Program — a unique creator ecosystem designed to do one thing: increase the opportunity found in creator-brand alignment.
This isn't your typical affiliate setup. It's built to give creators real business power — not just promo codes — with the goal of unlocking the full potential of the assets they bring, when utilized properly. InStyler CEO Dan Fugardi believes most brands still fall short in making that potential fully available to the creator community. 'This program is meant to go beyond what most would consider healthy and create an atypically well-compensated and aligned relationship with our creators. This, at least, is our hope as we continue to develop the program,' said Fugardi, whose passion for community empowerment helped shape the program's foundation.
'We're about to launch a product that could disrupt the industry in a way that beats everything before it,' Fugardi added. 'With this affiliate construct, we doubled down on building something unique for marketing partners in today's shifting influencer space. We'll continue to refine this as we receive feedback, but our guiding principle is simple: lead with revenue, while investing more in the people behind the all-important buzz of a launch.'
This program is also packed with exclusive surprises, brand-building bonuses, and access layers you won't find anywhere else. Here's the twist: you have to join and be accepted to see everything that's inside.
With Cole Wetzler's Mobius Digital supporting the upcoming rollouts, Fugardi has once again tapped Arin Meyer for oversight — his clear strategic constant when operations need to land clean. Following the public praise of her pivotal role in the company's turnaround, this latest step further establishes Meyer as a key driver in translating strategy into execution. Also joining the collective is board member Vicki Nguyen, who — similar to Wetzler — leads a strategic, PE-style brand portfolio that she is aggressively expanding across the South Pacific and Europe. With several recent acquisitions, Nguyen's growing portfolio is helping chart the course for the affiliate program's future expansion.
Program Highlights:
Surprise Perks – Exclusive content vaults, private training drops, and brand collabs — available only to active members.
Business-Builder Bonuses – AI tools, strategy sessions, UGC accelerators, brand party vouchers and more — designed to grow your brand, not just InStyler's.
Passive Income – The program is designed to benefit from the groundwork done with InStyler on this or future business.
More than an affiliate program, this is a launchpad. And it's built for creators who are ready to go all in.
Applications are open for the first time and found at InStyler's exclusive mobile pop shop: https://affiliate.popbyinstyler.com
Spots are limited . . . and what's behind the curtain is truly worth discovering.
Press Contact: [email protected]
Partnership Inquiries: https://affiliate.popbyinstyler.com
Jessica del Mundo
10storyhouse
[email protected]
Visit us on social media:
YouTube
TikTok
X
Other
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironrasib Company entered into $2 billion flexible funding agreement with Royalty Pharma to support bold vision for global development and commercialization Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2025, and provided an update on corporate progress. The company continues to make meaningful progress on its near-term strategic priorities: Execute pivotal trials with daraxonrasib monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) RASolute 302, a global Phase 3 trial of daraxonrasib in patients with previously treated PDAC, continues to enroll well. The company is winding down enrollment in the U.S. while continuing to enroll patients outside the U.S. to support global registration. The company expects to complete enrollment in this trial this year to enable an expected data readout in 2026. The company recently announced that daraxonrasib received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for previously treated metastatic PDAC in patients with KRAS G12 mutations. In RASolve 301, a global Phase 3 trial of daraxonrasib in patients with previously treated NSCLC, the company continues enrolling patients in the U.S. and is now activating trial sites in Europe and Japan. Advance daraxonrasib into earlier line randomized pivotal trials in patients with PDAC and NSCLC The company remains on track to initiate a registrational trial this year with daraxonrasib as first line treatment for patients with metastatic PDAC; this is planned as a three-arm trial comparing daraxonrasib or daraxonrasib plus chemotherapy to chemotherapy. Later this year, the company expects to share the trial design and clinical combination data that informed this planned trial. The company also remains on track to initiate a registrational trial this year with daraxonrasib as adjuvant treatment for patients with resectable PDAC and expects to share the trial design later this year. Based on new clinical data disclosed by the company last quarter indicating that daraxonrasib can be combined productively with pembrolizumab with or without platinum doublet chemotherapy as a first line treatment of patients with RAS mutant NSCLC, the company expects to initiate a Phase 3 registrational trial in this indication in 2026. Generate sufficient data to inform development priorities for the mutant-selective inhibitors elironrasib and zoldonrasib and prepare to initiate one or more pivotal trials either as monotherapy or in a drug combination The company continues to study its mutant-selective inhibitors elironrasib and zoldonrasib as monotherapy and in drug combinations. The company recently reported an updated clinical data set from patients with previously treated KRAS G12C NSCLC treated with elironrasib as monotherapy that showed a highly competitive profile, including differentiated safety and tolerability along with a compelling objective response rate and progression-free survival. The company also showed clinical evidence that elironrasib can be combined productively with pembrolizumab in first line NSCLC patients with an acceptable safety and tolerability profile. Further, the company recently announced that elironrasib received FDA Breakthrough Therapy Designation for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor. The company believes this designation is a recognition of the significant unmet medical need and elironrasib's potential to serve these patients. Currently there are no RAS-targeted inhibitors with full FDA approval for treating patients with KRAS G12C NSCLC. For zoldonrasib, clinical data presented in April demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D NSCLC, which follows encouraging data reported previously in patients with KRAS G12D PDAC. The company expects to initiate one or more pivotal combination trials in 2026 that incorporate either zoldonrasib or elironrasib. Progress earlier stage pipeline, including advancing next-generation innovations from the company's highly productive discovery organization Clinical development of RMC-5127, a RAS(ON) G12V-selective inhibitor, remains on track to reach a clinic-ready stage in 2025 to enable an expected Phase 1 initiation in 2026. The company also continues to invest in collaborations designed to enhance its discovery efforts, recently announcing a drug discovery collaboration with Iambic Therapeutics, in which Iambic will use its cutting-edge AI capabilities to generate customized models through training with Revolution Medicines' proprietary data. This collaboration aims to enhance Revolution Medicines' lead discovery and optimization processes directed against both current and new drug targets to ensure the company continues building a highly impactful and sustainable pipeline. Grow global commercialization and operational capabilities and advance launch readiness The company recently announced a partnership with Royalty Pharma, which provides $2 billion in committed capital to Revolution Medicines upon achievement of agreed-upon milestones through a flexible mix of synthetic royalty and debt instruments. This flexible funding agreement provides the company with strategic agility and ability to secure the resources needed to advance its ambitious global clinical development and commercialization plans. The company continues to grow its commercial and operational capabilities and increase activities in support of a potential launch. 'As we advance our innovative RAS(ON) inhibitors through late-stage development and prepare for potential commercialization, we are scaling the effort to meet the ever-growing opportunities afforded by our pipeline,' said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. 'With our maturing pipeline, organizational capabilities and recently bolstered financial wherewithal, we are on a path toward becoming a fully integrated, global oncology company with an industry-leading franchise of targeted therapies for patients with RAS-addicted cancers.' Other Corporate Updates Building on recently disclosed clinical data supporting combinations of its RAS(ON) inhibitors with pembrolizumab, a leading PD-1 antibody, the company announced that it had entered into a clinical collaboration with Summit Therapeutics in multiple solid tumor settings to evaluate the safety and efficacy of Revolution Medicines' clinical-stage RAS(ON) inhibitors in combination with Summit Therapeutics' ivonescimab, an innovative PD-1 / VEGF bispecific antibody. Financial Highlights Second Quarter Results Cash Position: Cash, cash equivalents and marketable securities were $2.1 billion as of June 30, 2025. This balance includes receipt of the first $250 million royalty monetization tranche from Royalty Pharma. R&D Expenses: Research and development expenses were $224.1 million for the quarter ended June 30, 2025, compared to $134.9 million for the quarter ended June 30, 2024. The increase in expenses was primarily due to increases in clinical trial expenses and manufacturing expenses for daraxonrasib, zoldonrasib and elironrasib, and personnel-related expenses and stock-based compensation expense related to additional headcount. G&A Expenses: General and administrative expenses were $40.6 million for the quarter ended June 30, 2025, compared to $21.7 million for the quarter ended June 30, 2024. The increase was primarily due to increases in personnel-related expenses and stock-based compensation expense associated with additional headcount, and an increase in commercial preparation activities. Net Loss: Net loss was $247.8 million for the quarter ended June 30, 2025, compared to net loss of $133.2 million for the quarter ended June 30, 2024. Financial GuidanceRevolution Medicines is projecting full year 2025 GAAP net loss guidance of between $1.03 billion and $1.09 billion, which includes estimated non-cash stock-based compensation expense of between $115 million and $130 million. WebcastRevolution Medicines will host a webcast this afternoon, August 6, 2025, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). To listen to the live webcast, or access the archived webcast, please visit: Following the live webcast, a replay will be available on the company's website for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered 'forward-looking statements,' including without limitation statements regarding the company's financial projections and guidance; the company's development opportunities, plans and timelines and its ability to build or advance its portfolio and R&D pipeline; progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company's candidates being studied; the company's expectations regarding timing of clinical trial initiation, enrollment and data readouts or disclosures and clinical trial designs; collaborations, including the aims and expected benefits of the Company's collaboration with Iambic; sources of capital, including the availability of capital under the Royalty Pharma arrangement and whether the company achieves the milestones associated with certain payments thereunder. Forward-looking statements are typically, but not always, identified by the use of words such as 'aims,' 'anticipate,' "believe," "estimate," "expect," "plan," 'potential,' 'project,' 'up to,' "will" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company's development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company's programs' development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company's business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on August 6, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events. Revolution Medicines Media & Investor Contact:media@ investors@ REVOLUTION MEDICINES, CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share data)(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 224,134 $ 134,932 $ 429,883 $ 252,953 General and administrative 40,580 21,711 75,591 44,549 Total operating expenses 264,714 156,643 505,474 297,502 Loss from operations (264,714 ) (156,643 ) (505,474 ) (297,502 ) Other income (expense), net: Interest income 22,404 21,487 47,319 45,247 Interest and other income (expense), net (899 ) 16 (909 ) (2,793 ) Change in fair value of warrant liabilities and contingent earn-out shares (4,578 ) 1,907 (2,139 ) 5,812 Total other income, net 16,927 23,410 44,271 48,266 Loss before income taxes (247,787 ) (133,233 ) (461,203 ) (249,236 ) Net loss $ (247,787 ) $ (133,233 ) $ (461,203 ) $ (249,236 ) Net loss per share attributable to common stockholders, basic and diluted $ (1.31 ) $ (0.81 ) $ (2.45 ) $ (1.51 ) Weighted-average common shares used to compute net loss per share, basic and diluted 188,583,288 165,141,936 188,365,805 164,935,542 REVOLUTION MEDICINES, CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, unaudited) June 30, 2025 December 31, 2024 Cash, cash equivalents and marketable securities $ 2,137,171 $ 2,289,299 Working capital (1) 1,991,905 2,163,718 Total assets 2,429,568 2,558,301 Total liabilities 564,199 293,097 Total stockholders' equity 1,865,369 2,265,204 (1) Working capital is defined as current assets less current in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
BrightView Posts Third Quarter Fiscal 2025 Earnings With Record Net Income and Adjusted EBITDA, and Reaffirms Full Year Guidance
BLUE BELL, Pa., August 06, 2025--(BUSINESS WIRE)--BrightView Holdings, Inc. (NYSE: BV) (the "Company" or "BrightView"), the leading commercial landscaping services company in the United States, today reported unaudited results for the third quarter ended June 30, 2025. THIRD QUARTER FISCAL 2025 SUMMARY Net service revenues decreased 4.1% year-over-year to $708.3 million, Net income increased $8.8 million year-over-year to $32.3 million, Net income margin expansion of 140 basis points, Adjusted EBITDA2 increased 4.9% year-over-year to $113.2 million, Adjusted EBITDA margin2 expansion of 140 basis points, Year-to-date Net cash provided by operating activities of $207.4 million, an increase of $55.3 million, Year-to-date Adjusted Free Cash Flow2 of $25.8 million, a decrease of $94.4 million. COMPANY REAFFIRMS FISCAL YEAR 2025 GUIDANCE1 FY25 Guidance Total Revenue $2.68B to $2.73B Adjusted EBITDA2 $348M to $362M Adjusted EBITDA Margin2 ~130bps Adjusted Free Cash Flow2 $60M to $75M "We continue to execute on our One BrightView strategy, which is underpinned by prioritizing our employees and delivering best-in-class service to our customers," said Dale Asplund, BrightView President and Chief Executive Officer. "Our record year-to-date Adjusted EBITDA and Adjusted EBITDA margin reflect the meaningful progress of our transformation as we continue to focus on driving sustained, long-term profitable growth and shareholder value." _______________1 For assumptions underlying the fiscal year 2025 guidance, see the Q3 2025 presentation at Adjusted EBITDA, Adjusted EBITDA margin, and Adjusted Free Cash Flow are non-GAAP measures. Refer to the "Non-GAAP Financial Measures" section for more information. The Company is not providing quantitative reconciliations of its financial outlook for Adjusted EBITDA to net income, or Adjusted Free Cash Flow to Cash flows provided by operating activities, the corresponding GAAP measures, because the respective GAAP measures that are excluded from the non-GAAP financial outlook are difficult to reliably predict or estimate without unreasonable effort due to their dependence on future uncertainties, such as items discussed below. Additionally, information that is currently not available to the Company could have a potentially unpredictable & potentially significant impact on its future GAAP financial results. Fiscal 2025 Results – Total BrightView Total BrightView - Operating Highlights Three Months Ended June 30, Nine Months Ended June 30, ($ in millions, except per share figures) 2025 2024 Change 2025 2024 Change Revenue $ 708.3 $ 738.8 (4.1%) $ 1,970.0 $ 2,038.4 (3.4%) Net Income $ 32.3 $ 23.5 37.4% $ 28.3 $ 40.8 (30.6%) Net Income Margin 4.6 % 3.2 % 140 bps 1.4 % 2.0 % (60) bps Adjusted EBITDA $ 113.2 $ 107.9 4.9% $ 238.8 $ 219.5 8.8% Adjusted EBITDA Margin 16.0 % 14.6 % 140 bps 12.1 % 10.8 % 130 bps Net income available to common shareholders $ 14.9 $ 9.3 60.2% $ 1.0 $ 9.0 (88.9%) Weighted average number of common shares outstanding 95.2 94.5 0.7% 95.3 94.7 0.6% Basic Earnings per Share $ 0.16 $ 0.10 60.0% $ 0.01 $ 0.09 (88.9%) Adjusted Net Income $ 45.5 $ 48.3 (5.8%) $ 72.6 $ 68.1 6.6% Adjusted weighted average number of common shares outstanding 149.5 148.8 0.5% 149.6 148.8 0.5% Adjusted Earnings per Share $ 0.30 $ 0.32 (6.3%) $ 0.48 $ 0.46 4.3% Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, and Adjusted weighted average number of common shares outstanding are non-GAAP measures. Refer to the "Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Measures" sections for more information. Basic Earnings (Loss) per Share is determined by dividing Net Income (Loss) available to common shareholders by the Weighted average number of common shares outstanding. Net income (Loss) available to common shareholders is calculated as Net Income (Loss) less dividends declared on Series A Convertible Preferred Shares and Earnings allocated to Convertible Preferred Shares For the three months ended June 30, 2025, total revenue decreased 4.1% to $708.3 million driven by a $13.7 million decrease in our development services revenue due to timing delays in development projects, combined with a $13.3 million year over year decrease in our commercial landscaping business, primarily driven by a decline in commercial landscaping services. For the nine months ended June 30, 2025, total revenue decreased 3.4% to $1,970.0 million driven by a $56.1M million decrease in our commercial landscaping business combined with a $10.5 million decrease in snow removal revenue, both of which were primarily driven by strategic reductions of non-core businesses and to a lesser extent a decline in commercial landscaping and snow in our core business. Fiscal 2025 Results – Segments Maintenance Services - Operating Highlights Three Months Ended June 30, Nine Months Ended June 30, ($ in millions) 2025 2024 Change 2025 2024 Change Landscape Maintenance $ 502.9 $ 516.2 (2.6%) $ 1,200.2 $ 1,256.3 (4.5%) Snow Removal $ 5.9 $ 8.5 (30.6%) $ 210.7 $ 221.2 (4.7%) Total Revenue $ 508.8 $ 524.7 (3.0%) $ 1,410.9 $ 1,477.5 (4.5%) Adjusted EBITDA $ 81.7 $ 80.4 1.6% $ 172.7 $ 166.9 3.5% Adjusted EBITDA Margin 16.1 % 15.3 % 80 bps 12.2 % 11.3 % 90 bps Capital Expenditures $ 98.3 $ 16.8 485.1% $ 171.3 $ 34.7 393.7% For the third quarter of fiscal 2025, revenue in the Maintenance Services Segment decreased by $15.9 million, or 3.0%, from the 2024 period. Commercial Landscaping services decreased by $13.3 million, or 2.6% and snow removal services decreased by $2.6 million or 30.6%. The decrease in commercial landscaping was underpinned by a decline in a combination of contract services and ancillary services. Adjusted EBITDA for the Maintenance Services Segment for the three months ended June 30, 2025, increased by $1.3 million to $81.7 million from $80.4 million in the 2024 period. Segment Adjusted EBITDA Margin increased 80 basis points, to 16.1%, in the three months ended June 30, 2025, from 15.3% in the 2024 period. The increase in Segment Adjusted EBITDA Margin was primarily driven by cost management initiatives, which included reduced vehicle and equipment related costs, and personnel related costs. These savings offset the decrease in revenues described above. For the nine months ended June 30, 2025, Maintenance Services net service revenues decreased by $66.6 million, or 4.5%, from the 2024 period. Commercial Landscaping services decreased by $56.1 million, or 4.5% and snow removal services decreased by $10.5 million, or 4.7%. The decrease was primarily driven by strategic reductions of non-core businesses and to a lesser extent a decline in commercial landscaping in our core business. Adjusted EBITDA for the Maintenance Services Segment for the nine months ended June 30, 2025, increased by $5.8 million to $172.7 million from $166.9 million in the 2024 period. Segment Adjusted EBITDA Margin increased 90 basis points, to 12.2%, in the nine months ended June 30, 2025, from 11.3% in the 2024 period. The increase in Segment Adjusted EBITDA and Adjusted EBITDA Margin was primarily driven by lower personnel related costs, and vehicle and equipment related costs a result of the Company's cost management initiatives. These savings more than offset the decrease in revenues described above. Development Services - Operating Highlights Three Months Ended June 30, Nine Months Ended June 30, ($ in millions) 2025 2024 Change 2025 2024 Change Revenue $ 201.3 $ 215.0 (6.4%) $ 565.0 $ 564.8 0.0% Adjusted EBITDA $ 31.5 $ 27.5 14.5% $ 66.1 $ 52.6 25.7% Adjusted EBITDA Margin 15.6 % 12.8 % 280 bps 11.7 % 9.3 % 240 bps Capital Expenditures $ 5.2 $ 6.4 (18.8%) $ 24.5 $ 11.3 116.8% For the third quarter of fiscal 2025, revenue in the Development Services Segment decreased by $13.7 million, or 6.4%, compared to the 2024 period. The decrease was driven by timing delays in Development Services projects. Adjusted EBITDA for the Development Services Segment for the three months ended June 30, 2025, increased $4.0 million, to $31.5 million, compared to the 2024 period. Segment Adjusted EBITDA Margin increased 280 basis points, to 15.6% for the quarter from 12.8% in the 2024 period. The increases in Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin were primarily driven by reductions in overhead costs due to the Company's cost management initiatives combined with the timing and mix of projects in the period. For the nine months ended June 30, 2025, revenue in the Development Services Segment increased $0.2 million, or 0.0%, compared to the 2024 period. The results were driven by increased Development Services project volumes in the first half of fiscal 2025, which were offset by delays in the timing of projects during the third quarter. Adjusted EBITDA for the Development Services Segment for the nine months ended June 30, 2025, increased $13.5 million, to $66.1 million, compared to the 2024 period. Segment Adjusted EBITDA Margin increased 240 basis points, to 11.7% for the period from 9.3% in the 2024 period. The increases in Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin were primarily driven by reductions in overhead costs due to the Company's cost management initiatives, combined with the timing and mix of projects in the period. Total BrightView Cash Flow Metrics Nine Months Ended June 30, ($ in millions) 2025 2024 Change Net Cash Provided by Operating Activities $ 207.4 $ 152.1 36.4% Adjusted Free Cash Flow $ 25.8 $ 120.2 (78.5%) Capital Expenditures $ 195.8 $ 46.0 325.7% Net cash provided by operating activities for the nine months ended June 30, 2025, increased $55.3 million, to $207.4 million, from $152.1 million in the 2024 period. This increase was due to a decrease in net income, more than offset by increases in non-cash adjustments to reconcile net income to net cash provided by operating activities, combined with an increase in cash provided by accounts receivable. This was partially offset by a decrease in cash provided by other operating assets. Adjusted Free Cash Flow decreased $94.4 million to $25.8 million for the nine months ended June 30, 2025, from $120.2 million in the prior year. The decrease in Adjusted Free Cash Flow was due to an increase in cash used for capital expenditures, partially offset by an increase in net cash provided by operating activities. For the nine months ended June 30, 2025, capital expenditures were $195.8 million, compared with $46.0 million in the prior year. The Company also generated proceeds from the sale of property and equipment of $14.2 million and $14.1 million during the nine months ended June 30, 2025 and 2024, respectively. Net of proceeds from the sale of property and equipment, net capital expenditures represented 9.2% of revenue in the nine months ended June 30, 2025, compared to 1.6% for the nine months ended June 30, 2024. Total BrightView Balance Sheet Metrics ($ in millions) June 30, 2025 September 30, 2024 June 30, 2024 Total Financial Debt1 $ 876.8 $ 877.3 $ 885.3 Minus: Total Cash & Equivalents 79.1 140.4 115.9 Total Net Financial Debt2 $ 797.7 $ 736.9 $ 769.4 Total Net Financial Debt to Adjusted EBITDA ratio3 2.3x 2.3x 2.4x 1Total Financial Debt includes total long-term debt, net of original issue discount, and finance lease obligations. 2Total Net Financial Debt equals Total Financial Debt minus Total Cash & Equivalents. 3Total Net Financial Debt to Adjusted EBITDA ratio equals Total Net Financial Debt divided by the trailing twelve month Adjusted EBITDA. As of June 30, 2025, the Company's Total Net Financial Debt was $797.7 million, an increase of $60.8 million compared to $736.9 million as of September 30, 2024. The Company's Total Net Financial Debt to Adjusted EBITDA ratio was 2.3x as of June 30, 2025, compared to 2.3x as of September 30, 2024. Conference Call Information A conference call to discuss the third quarter fiscal 2025 financial results is scheduled for August 7, 2025, at 8:30 a.m. EDT. The U.S. toll-free dial-in for the conference call is (800) 274-8461 and the international dial-in is +1 (203) 518-9814. The Conference Access Code is BRIGHT. A live audio webcast of the conference call will be available on the Company's investor website where presentation materials will be posted prior to the call. A replay of the call will be available until 11:59 p.m. EDT on August 21, 2025. To access the recording, dial (800) 839-5495 (Access Code 27525). A link to the current Earnings Call slides can be found at About BrightView BrightView (NYSE: BV), the nation's largest commercial landscaper, proudly designs, creates, and maintains some of the best landscapes on Earth and provides the most efficient and comprehensive snow and ice removal services. With a dependable service commitment, BrightView brings brilliant landscapes to life at premier properties across the United States, including business parks and corporate offices, homeowners' associations, healthcare facilities, educational institutions, retail centers, resorts and theme parks, municipalities, golf courses, and sports venues. BrightView also serves as the Official Field Consultant to Major League Baseball. Through industry-leading best practices and sustainable solutions, BrightView is invested in taking care of our team members, engaging our clients, inspiring our communities, and preserving our planet. Visit and connect with us on X, Facebook, and LinkedIn. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts included in this presentation, including statements concerning our plans, objectives, goals, beliefs, business outlook, business trends, expectations regarding our industry, strategy, future events, future operations, future liquidity and financial position, future revenues, projected costs, prospects, plans and objectives of management and other information, may be forward-looking statements. Words such as "believes," "expects," "may," "will," "should," "seeks," "intends," "plans," "estimates," or "anticipates," and variations of such words or similar expressions are intended to identify forward-looking statements. The forward-looking statements are not historical facts or guarantees of future performance and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and projections will result or be achieved, and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Factors that could cause actual results to differ materially from those projected include, but are not limited to: competitive industry pressures; our ability to preserve long-term customer relationships; a determination by customers to reduce their outsourcing or use of preferred vendors; inconsistent practices and the operating results of individual branches; our ability to implement our business strategies and achieve our growth objectives; impacts of future acquisitions or other strategic transactions; the possibility that costs or difficulties related to the integration of acquired businesses' operations will be greater than expected and the possibility that integration efforts will disrupt our business and strain management time and resources; the potential impacts on revenues and our financial condition caused by any disposition of assets or discontinuation of lines of business; the seasonal nature of our landscape maintenance services; our dependence on weather conditions and the impact of severe weather and climate change on our business; disruptions in our supply chain and changes in our ability to source adequate supplies and materials in a timely manner; changes in general economic conditions can result in delays in construction activities which can adversely affect our development services segment; any failure to accurately estimate the overall risk, requirements, or costs when we bid on or negotiate contracts that are ultimately awarded to us and, for such contracts, the ability to collect amounts owed under such contracts; the conditions and periodic fluctuations of the new commercial construction sector, as well as spending on repair and upgrade activities; the level, timing and location of snowfall; our ability to retain or hire our executive management and other key personnel; our ability to attract, retain and maintain positive relations with workers; any failure to properly verify employment eligibility of our employees; the liability exposure from our use of subcontractors to perform work under certain customer contracts; our recognition of future impairment charges; laws and governmental regulations, including those relating to employees, wage and hour, immigration, human health, safety, transportation and the associated financial impact of such regulations; environmental, health and safety laws and regulations, including laws pertaining to the use of pesticides, herbicides and fertilizers, or liabilities thereunder, as well as the related risk of potential litigation; the distraction and impact caused by litigation, of adverse litigation judgments and settlements resulting from legal proceedings; tax increases and changes in tax rules; any increase in on-job accidents involving employees; any failure, inadequacy, interruption, security failure or breach of our information technology systems; compliance with data privacy regulations; any adverse consequences of our substantial indebtedness; our ability to adequately protect our intellectual property; increases in interest rates governing our variable rate indebtedness increasing the cost of servicing our substantial indebtedness; risks related to counterparty credit worthiness or non-performance of the derivative financial instruments we utilize; restrictions within our debt agreements that limit our flexibility in operating; our ability to generate sufficient cash flow to satisfy our significant debt service obligations; the incurrence of substantially more debt, including off-balance sheet financing, contractual obligations and general and commercial liabilities; any failure to extend credit under our facility or reduce the borrowing base under our Revolving Credit Facility; any future sales, or the perception of future sales, by us or our affiliates, which could cause the market price for our common stock to decline; the ability of KKR and One Rock to exert significant influence over us; anti-takeover provisions in our organizational documents that could delay or prevent a change in control; the authorization of our Board of Directors to issue and designate shares of our preferred stock in additional series without stockholder approval; the fact that the holders of our Series A Preferred Stock may have different interests from and vote their shares in a manner deemed adverse to, holders of our common stock; the dividend, liquidation, and redemption rights of the holders of our Series A Preferred Stock; our certificate of incorporation restricting all stockholder litigation matters to the Court of Chancery of the State of Delaware and the federal district courts of the United States of America; general business, economic, and financial market conditions; increases in raw material costs, fuel prices, wages and other operating costs, and changes in our ability to source adequate supplies and materials in a timely manner; occurrence of natural disasters, terrorist attacks, global health emergencies and other external events; heightened inflation, geopolitical conflicts, recession, financial market disruptions, trade policies and tariffs, and other economic conditions; environmental, social and governance matters and/or our reporting of such matters; significant changes in our stock price and its ability for resale; securities analysts' reports about our business or their downgrade of our stock or sector; maintaining effective internal controls; and costs and requirements imposed as a result of maintaining compliance with the requirements of being a public company. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found under "Item 1A. Risk Factors" in our Form 10-K for the fiscal year ended September 30, 2024, and such factors may be updated from time to time in our periodic filings with the Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any forward-looking statement made in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Non-GAAP Financial Measures To supplement the Company's financial information presented in accordance with GAAP and aid understanding of the Company's business performance, the Company uses certain non-GAAP financial measures, namely "Adjusted EBITDA", "Adjusted EBITDA Margin", "Adjusted Net Income (Loss)", "Adjusted Earnings (Loss) per Share", "Adjusted Free Cash Flow", "Total Financial Debt", "Total Net Financial Debt" and "Total Net Financial Debt to Adjusted EBITDA ratio". We believe Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio assist investors in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management regularly uses these measures as tools in evaluating our operating performance, financial performance and liquidity. Management uses Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio to supplement comparable GAAP measures in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. In addition, we believe that Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio are frequently used by investors and other interested parties in the evaluation of issuers, many of which also present Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio when reporting their results in an effort to facilitate an understanding of their operating and financial results and liquidity. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. Adjusted EBITDA: We define Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization, as further adjusted to exclude certain non-cash, non-recurring and other adjustment items. Adjusted EBITDA Margin: We define Adjusted EBITDA Margin as Adjusted EBITDA, defined above, divided by Net Service Revenues. Adjusted Net Income (Loss): We define Adjusted Net Income (Loss) as net income (loss) including interest and depreciation, and excluding other items used to calculate Adjusted EBITDA and further adjusted for the tax effect of these exclusions and the removal of the discrete tax items. Adjusted Earnings per Share: We define Adjusted Earnings per Share as Adjusted Net Income divided by the (i) weighted average number of common shares outstanding used in the calculation of basic earnings per share plus (ii) shares of common stock related to the Series A Preferred Stock on an as-converted basis, assumed to be converted for the entire period. The addition of shares of common stock related to the Series A Convertible Preferred Stock on an as-converted basis reflects the dilutive impact of the potential conversion of the Series A Preferred Stock and is expected to provide comparability in future periods. Adjusted Free Cash Flow: We define Adjusted Free Cash Flow as cash flows from operating activities less capital expenditures, net of proceeds from the sale of property and equipment. Total Financial Debt: We define Total Financial Debt as total long-term debt, net of original issue discount, and finance lease obligations. Total Net Financial Debt: We define Total Net Financial Debt as Total Financial Debt minus total cash and cash equivalents. Total Net Financial Debt to Adjusted EBITDA ratio: We define Total Net Financial Debt to Adjusted EBITDA ratio as Total Net Financial Debt divided by the trailing twelve month Adjusted EBITDA. Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income (Loss), Adjusted Earnings (Loss) per Share, Adjusted Free Cash Flow, Total Financial Debt, Total Net Financial Debt, and Total Net Financial Debt to Adjusted EBITDA ratio are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or the ratio of net income (loss) to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of Adjusted Free Cash Flow available for management's discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to the same or other similarly titled measures of other companies and can differ significantly from company to company. BrightView Holdings, Inc. Consolidated Balance Sheets (Unaudited) (in millions)* June 30, 2025 September 30, 2024 Assets Current assets: Cash and cash equivalents $ 79.1 $ 140.4 Accounts receivable, net 396.2 415.2 Unbilled revenue 108.9 137.8 Other current assets 81.1 86.7 Total current assets 665.3 780.1 Property and equipment, net 493.1 391.9 Intangible assets, net 73.5 95.8 Goodwill 2,015.7 2,015.7 Operating lease assets 74.6 81.3 Other assets 35.0 27.0 Total assets $ 3,357.2 $ 3,391.8 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 120.4 $ 144.1 Deferred revenue 99.7 83.8 Current portion of self-insurance reserves 57.2 52.8 Accrued expenses and other current liabilities 207.2 237.7 Current portion of operating lease liabilities 24.8 24.9 Total current liabilities 509.3 543.3 Long-term debt, net 790.7 802.5 Deferred tax liabilities 47.2 43.9 Self-insurance reserves 124.7 112.8 Long-term operating lease liabilities 55.8 62.6 Other liabilities 42.8 44.3 Total liabilities 1,570.5 1,609.4 Mezzanine equity: Series A convertible preferred shares, $0.01 par value, 7% cumulative dividends; 500,000 shares issued and outstanding as of June 30, 2025 and September 30, 2024, aggregate liquidation preference of $512.0 as of June 30, 2025 and September 30, 2024 507.1 507.1 Stockholders' equity: Preferred stock, $0.01 par value; 50,000,000 shares authorized; no shares issued or outstanding as of June 30, 2025 and September 30, 2024 — — Common stock, $0.01 par value; 500,000,000 shares authorized; 109,500,000 and 108,200,000 shares issued and 95,000,000 and 94,800,000 shares outstanding as of June 30, 2025 and September 30, 2024, respectively 1.1 1.1 Treasury stock, at cost; 14,500,000 and 13,400,000 shares as of June 30, 2025 and September 30, 2024, respectively (188.1 ) (173.5 ) Additional paid-in capital 1,507.8 1,518.1 Accumulated deficit (40.6 ) (68.9 ) Accumulated other comprehensive (loss) (0.6 ) (1.5 ) Total stockholders' equity 1,279.6 1,275.3 Total liabilities, mezzanine equity and stockholders' equity $ 3,357.2 $ 3,391.8 (*) Amounts may not total due to rounding. BrightView Holdings, Inc. Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Nine Months Ended June 30, 2025 2024 2025 2024 (in millions)* Net service revenues $ 708.3 $ 738.8 $ 1,970.0 $ 2,038.4 Cost of services provided 537.4 561.2 1,524.8 1,575.0 Gross profit 170.9 177.6 445.2 463.4 Selling, general and administrative expense 106.2 120.1 343.5 375.0 Gain on divestiture - (0.1 ) - (44.0 ) Amortization expense 7.1 8.6 22.3 27.4 Income from operations 57.6 49.0 79.4 105.0 Other (income) expense (0.7 ) 0.5 0.1 (1.5 ) Interest expense, net 13.4 15.1 40.3 48.2 Income before income taxes 44.9 33.4 39.0 58.3 Income tax expense 12.6 9.9 10.7 17.5 Net income $ 32.3 $ 23.5 $ 28.3 $ 40.8 Less: Dividends on Series A convertible preferred shares 8.9 8.9 26.8 26.7 Net income attributable to common stockholders $ 23.4 $ 14.6 $ 1.5 $ 14.1 Earnings per share Basic earnings per share $ 0.16 $ 0.10 $ 0.01 $ 0.09 Diluted earnings per share $ 0.15 $ 0.10 $ 0.01 $ 0.09 BrightView Holdings, Inc. Net Loss (Income) Available to Common Shareholders (Unaudited) Three Months Ended June 30, Nine Months Ended June 30, 2025 2024 2025 2024 (in millions)* Net income $ 32.3 $ 23.5 $ 28.3 $ 40.8 Less: Dividends on Series A convertible preferred shares (8.9 ) (8.9 ) (26.8 ) (26.7 ) Less: Earnings allocated to Convertible Preferred Shares (8.5 ) (5.3 ) (0.5 ) (5.1 ) Net income available to common shareholders $ 14.9 $ 9.3 $ 1.0 $ 9.0 BrightView Holdings, Inc. Segment Reporting (Unaudited) Three Months Ended June 30, Nine Months Ended June 30, 2025 2024 2025 2024 (in millions)* Maintenance Services $ 508.8 $ 524.7 $ ... 1,410.9 $ 1,477.5 Development Services 201.3 215.0 565.0 564.8 Eliminations (1.8 ) (0.9 ) (5.9 ) (3.9 ) Net Service Revenues $ 708.3 $ 738.8 $ 1,970.0 $ 2,038.4 Maintenance Services $ 98.3 $ 16.8 $ 171.3 $ 34.7 Development Services 5.2 6.4 24.5 11.3 Capital Expenditures $ 103.5 $ 23.2 $ 195.8 $ 46.0 Maintenance Services $ 81.7 $ 80.4 $ 172.7 $ 166.9 Development Services 31.5 27.5 66.1 52.6 Adjusted EBITDA $ 113.2 $ 107.9 $ 238.8 $ 219.5 (*) Amounts may not total due to rounding. BrightView Holdings, Inc. Consolidated Statements of Cash Flows (Unaudited) Nine Months Ended June 30, 2025 2024 (in millions)* Cash flows from operating activities: Net income $ 28.3 $ 40.8 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 101.2 79.8 Amortization of intangible assets 22.3 27.4 Amortization of financing costs and original issue discount 2.2 2.0 Loss on debt extinguishment 0.7 0.6 Deferred taxes 0.8 (10.1 ) Equity-based compensation 13.6 15.1 Realized gain on hedges (4.1 ) (8.5 ) Gain on divestiture — (44.0 ) Other non-cash activities (2.2 ) (6.0 ) Change in operating assets and liabilities: Accounts receivable 10.0 (9.9 ) Unbilled and deferred revenue 44.7 47.1 Other operating assets (3.5 ) 21.4 Accounts payable and other operating liabilities (6.6 ) (3.6 ) Net cash provided by operating activities 207.4 152.1 Cash flows from investing activities: Purchase of property and equipment (195.8 ) (46.0 ) Proceeds from sale of property and equipment 14.2 14.1 Proceeds from divestiture — 51.6 Other investing activities 2.4 3.2 Net cash (used) provided by investing activities (179.2 ) 22.9 Cash flows from financing activities: Repayments of finance lease obligations (38.4 ) (26.4 ) Repayments of receivables financing agreement (27.9 ) (82.2 ) Proceeds from receivables financing agreement, net of issuance costs 14.5 0.5 Debt issuance and prepayment costs (1.3 ) (2.4 ) Series A preferred stock dividend (26.9 ) (8.9 ) Proceeds from issuance of common stock, net of share issuance costs 2.8 1.3 Repurchase of common stock and distributions (14.5 ) (3.1 ) Contingent business acquisition payments (0.5 ) (4.7 ) Increase in book overdrafts 2.5 — Other financing activities 0.2 (0.2 ) Net cash (used) by financing activities (89.5 ) (126.1 ) Net change in cash and cash equivalents (61.3 ) 48.9 Cash and cash equivalents, beginning of period 140.4 67.0 Cash and cash equivalents, end of period $ 79.1 $ 115.9 Supplemental Cash Flow Information: Cash paid for income taxes, net $ 2.4 $ 14.8 Cash paid for interest $ 43.3 $ 61.9 Non-cash Series A Preferred Stock dividends $ — $ 8.9 Accrual for property and equipment $ 9.1 $ 21.3 (*) Amounts may not total due to rounding. BrightView Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) Three Months Ended June 30, Nine Months Ended June 30, (in millions)* 2025 2024 2025 2024 Adjusted EBITDA Net income $ 32.3 $ 23.5 $ 28.3 $ 40.8 Income tax expense 12.6 9.9 10.7 17.5 Interest expense, net 13.4 15.1 40.3 48.2 Depreciation expense 38.9 28.1 101.2 79.8 Amortization expense 7.1 8.6 22.3 27.4 Business transformation and integration costs (a) 4.2 17.1 21.2 33.9 Gain on divestiture (b) — (0.1 ) — (44.0 ) Equity-based compensation (c) 4.7 5.1 14.1 15.3 Debt extinguishment (d) — 0.6 0.7 0.6 Adjusted EBITDA $ 113.2 $ 107.9 $ 238.8 $ 219.5 Adjusted Net Income Net income $ 32.3 $ 23.5 $ 28.3 $ 40.8 Amortization expense 7.1 8.6 22.3 27.4 Business transformation and integration costs (a) 4.2 17.1 21.2 33.9 Gain on divestiture (b) — (0.1 ) — (44.0 ) Equity-based compensation (c) 4.7 5.1 14.1 15.3 Debt extinguishment (d) — 0.6 0.7 0.6 Income tax adjustment (e) (2.8 ) (6.5 ) (14.0 ) (5.9 ) Adjusted Net Income $ 45.5 $ 48.3 $ 72.6 $ 68.1 Adjusted Free Cash Flow Cash flows provided by operating activities $ 55.8 $ 42.7 $ 207.4 $ 152.1 Minus: Capital expenditures 103.6 23.2 195.8 46.0 Plus: Proceeds from sale of property and equipment 6.5 11.5 14.2 14.1 Adjusted Free Cash Flow $ (41.3 ) $ 31.0 $ 25.8 $ 120.2 Adjusted Earnings per Share Numerator: Adjusted Net Income $ 45.5 $ 48.3 $ 72.6 $ 68.1 Denominator: Weighted average number of common shares outstanding – basic 95,228,000 94,549,000 95,302,000 94,668,000 Plus: Dilutive impact of Series A convertible preferred stock as-converted 54,242,000 54,242,000 54,242,000 54,127,000 Adjusted weighted average number of common shares outstanding 149,470,000 148,791,000 149,544,000 148,795,000 Adjusted Earnings per Share $ 0.30 $ 0.32 $ 0.48 $ 0.46 (*) Amounts may not total due to rounding. BrightView Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (a) Business transformation and integration costs consist of (i) severance and related costs; (ii) business integration costs and (iii) information technology infrastructure, transformation costs, and other. Three Months Ended June 30, Nine Months Ended June 30, (in millions)* 2025 2024 2025 2024 Severance and related costs $ — $ 4.3 $ (0.4 ) $ 10.5 Business integration (f) 0.2 0.4 — (0.5 ) IT, infrastructure, transformation, and other (g) 4.0 12.4 21.6 23.9 Business transformation and integration costs $ 4.2 $ 17.1 $ 21.2 $ 33.9 (b) Represents the realized gain on sale and transaction related expenses related to the divestiture of U.S. Lawns on January 12, 2024. (c) Represents equity-based compensation expense and related taxes recognized for equity incentive plans outstanding. (d) Represents losses on the extinguishment of debt related to Amendment No. 9 to the Credit Agreement, in the fiscal year ended September 30, 20025, and includes accelerated amortization of deferred financing fees and original issue discount as well as fees paid to lenders and third parties. (e) Represents the tax effect of pre-tax items excluded from Adjusted Net Income and the removal of the applicable discrete tax items, which collectively result in a reduction of income tax (benefit). The tax effect of pre-tax items excluded from Adjusted Net Income is computed using the statutory rate related to the jurisdiction that was impacted by the adjustment after taking into account the impact of permanent differences and valuation allowances. Discrete tax items include changes in laws or rates, changes in uncertain tax positions relating to prior years and changes in valuation allowances. Three Months Ended June 30, Nine Months Ended June 30, (in millions)* 2025 2024 2025 2024 Tax impact of pre-tax income adjustments $ 3.1 $ 6.9 $ 14.0 $ 19.3 Discrete tax items (0.3 ) (0.4 ) — (13.4 ) Income tax adjustment $ 2.8 $ 6.5 $ 14.0 $ 5.9 (f) Represents isolated expenses specifically related to the integration of acquired companies such as one-time employee retention costs, employee onboarding and training costs, fleet and uniform rebranding costs, and adjustments to performance based contingent consideration. The Company excludes Business integration costs from the measures disclosed above since such expenses vary in amount due to the number of acquisitions and size of acquired companies as well as factors specific to each acquisition, and as a result lack predictability as to occurrence and/or timing, and create a lack of comparability between periods. (g) Represents expenses related to distinct initiatives, typically significant enterprise-wide changes, including actions taken as part of the Company's One BrightView initiative. Such expenses are excluded from the measures disclosed above since such expenses vary in amount based on occurrence as well as factors specific to each of the activities, are outside of the normal operations of the business, and create a lack of comparability between periods. Total Financial Debt and Total Net Financial Debt (in millions)* June 30, 2025 September 30, 2024 June 30, 2024 Long-term debt, net $ 790.7 $ 802.5 $ 807.0 Plus: Current portion of long term debt — — — Financing costs, net 5.8 6.5 6.8 Present value of net minimum payment - finance lease obligations (h) 80.3 68.3 71.5 Total Financial Debt 876.8 877.3 885.3 Less: Cash and cash equivalents (79.1 ) (140.4 ) (115.9 ) Total Net Financial Debt $ 797.7 $ 736.9 $ 769.4 Total Net Financial Debt to Adjusted EBITDA ratio 2.3x 2.3x 2.4x (h) Balance is presented within Accrued expenses and other current liabilities and Other liabilities in the Consolidated Balance Sheet. (*) Amounts may not total due to rounding. Source: BrightView Landscapes View source version on Contacts For More Information: Investor Relations Chris Stoczko, Vice President of FinanceIR@ News Media David Freireich, Vice President of Communications & Public Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Motorola Solutions Completes Acquisition of Silvus Technologies Holding Inc.
Adds mobile ad-hoc network leadership and extends company into a multi-billion-dollar, rapidly growing addressable market for drone and unmanned systems CHICAGO, August 06, 2025--(BUSINESS WIRE)--Motorola Solutions (NYSE: MSI) has completed its acquisition of Silvus Technologies Holdings Inc. ("Silvus"), a global leader in mission-critical mobile ad-hoc networks (MANET), based in Los Angeles, California. Silvus' MANET technology is designed to support frontline operations in the most challenging and contested environments, enabling highly secure data, video and voice communications without the need for fixed infrastructure. Their devices mesh together to establish large, scalable and self-healing networks that adapt to continuous mobility. These robust mobile networks connect people, devices and other nodes over distance and at scale, and seamlessly support bandwidth-intensive technologies like video, sensors and drones. "Silvus' advanced solutions for drone and unmanned systems are trusted in the world's most demanding defense environments, and offer vital applications for border security and public safety," said Greg Brown, chairman and CEO, Motorola Solutions. "Their capabilities are an excellent complement to our land mobile radio and video technologies, and we look forward to bringing them to more customers around the world." Autonomous technologies, including drones, vehicles and robots, are increasingly deployed to safely provide a greater distance between soldiers and potential threats. Silvus' technology allows human operators to securely control these systems with extremely low latency, helping to save lives while informing better tactical decisions. Silvus' wide range of customers spans defense agencies, autonomous systems manufacturers, the intelligence community, law enforcement and enterprises globally. Motorola Solutions plans to extend Silvus' reach through its global scale and long-standing relationships with government and public safety customers around the world. "Working with Babak and the Silvus team, we've seen firsthand how their expertise has created truly disruptive communications technology," said Erik Fagan, Partner and Head of Industrial Technology, TJC. "They've built an exceptional company serving a critical need, and we are excited to watch their next successful chapter unfold with Motorola Solutions as a global leader in safety and security." "We have always respected Motorola Solutions' leadership," said Babak Daneshrad, PhD, CEO, Silvus Technologies. "At our core, both our companies are driven by innovation that makes the world safer. Bringing our advanced engineering teams together amplifies our ability to build more powerful solutions to serve more customers globally. I am incredibly optimistic about the future we have with Motorola Solutions." More information about the acquisition will be shared during Motorola Solutions' quarterly conference call with financial analysts at 4 p.m. Central (5 p.m. Eastern) on Aug. 7. The conference call will be webcast live and a replay will be available at Download video and images from the media kit. Transaction Terms Under the terms of the purchase agreement, the consideration for the Silvus acquisition includes $4.4 billion in upfront consideration, comprising approximately $4.38 billion in cash (subject to customary adjustments) and approximately $20 million in restricted stock to certain employee equity holders. The terms of the purchase agreement also include the ability to earn earnout consideration of up to $600 million in the aggregate based on business performance over consecutive twelve-month periods ending in 2027 and 2028. About Motorola Solutions | Solving for safer Safety and security are at the heart of everything we do at Motorola Solutions. We build and connect technologies to help protect people, property and places. Our solutions foster the collaboration that's critical for safer communities, safer schools, safer hospitals, safer businesses, and ultimately, safer nations. Learn more about our commitment to innovating for a safer future for us all at About TJC TJC, formerly known as The Jordan Company, has worked for more than 40 years with CEOs, founders and entrepreneurs across a range of industries including Consumer & Healthcare, Diversified Industrials, Industrial Technology, Aerospace & Defense, Logistics & Supply Chain and Technology & Infrastructure. With $32.0 billion of assets under management as of March 31, 2025, TJC is managed by a senior leadership team that has invested together for over 23 years on over 85 investments. TJC has offices in New York, Chicago, Miami and Stamford. For more information, please visit Motorola Solutions Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of applicable federal securities law. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and generally include words such as "believes," "expects," "intends," "anticipates," "estimates" and similar expressions. Motorola Solutions can give no assurance that any actual or future results or events discussed in these statements will be achieved. Any forward-looking statements represent Motorola Solutions' views only as of today and should not be relied upon as representing Motorola Solutions' views as of any subsequent date. Readers are cautioned that such forward-looking statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from the statements contained in this release. Such forward-looking statements include, but are not limited to, expected benefits of the transaction to Motorola Solutions and the Silvus business, the ability to expand the reach of Silvus' offerings, and our ability to integrate and combine the two companies. Motorola Solutions cautions the reader that the risks and uncertainties, including those in Part I Item 1A of Motorola Solutions' 2024 Annual Report on Form 10-K and in its other U.S. Securities and Exchange Commission ("SEC") filings, which are available for free on the SEC's website at and on Motorola Solutions' website at could cause actual results to differ materially from those estimated or predicted in the forward-looking statements. Many of these risks and uncertainties cannot be controlled by Motorola Solutions and factors that may impact forward-looking statements include, but are not limited to, Motorola Solutions' ability to successfully integrate and operate Silvus and realize the anticipated benefits of the acquisition. Motorola Solutions undertakes no obligation to publicly update any forward-looking statement or risk factor, whether as a result of new information, future events or otherwise. View source version on Contacts Media Contact Alexandra +1 312 965 3968 Investor Contact Tim YocumMotorola +1 847-576-6899
